Today: 10 June 2026
Browse Category

NASDAQ:IRON 17 October 2025 - 1 January 2026

Disc Medicine (NASDAQ: IRON) Stock Drops on FDA Voucher Speculation: Latest News, Analyst Forecasts, and What Investors Watch Next

Disc Medicine (NASDAQ: IRON) Stock Drops on FDA Voucher Speculation: Latest News, Analyst Forecasts, and What Investors Watch Next

Disc Medicine (NASDAQ: IRON) shares fell 11.5% to $80.04 on Dec. 20, 2025, after a STAT News report raised doubts about the effectiveness of its lead drug bitopertin and the FDA’s fast-track voucher process. The stock traded between $71.46 and $94.60 on heavy volume after Truist Securities cited the report, fueling concerns about the viability of accelerated approval.
20 December 2025
·
Disc Medicine (NASDAQ: IRON) Stock Tumbles on Insider-Selling Headlines as Bitopertin FDA Decision Nears — News, Analyst Forecasts, and What to Watch (Dec. 19, 2025)

Disc Medicine (NASDAQ: IRON) Stock Tumbles on Insider-Selling Headlines as Bitopertin FDA Decision Nears — News, Analyst Forecasts, and What to Watch (Dec. 19, 2025)

Disc Medicine (NASDAQ: IRON) shares fell about 10% to $81 in heavy trading Friday, after a series of insider sales by executives and directors appeared in SEC filings. The drop comes ahead of an expected FDA decision on bitopertin for EPP. CEO John Quisel, director Kevin Bitterman, and William Savage all disclosed recent stock sales. The stock had closed at $90.44 the prior session.
19 December 2025
·
Disc Medicine (IRON) Stock Soars on FDA Fast-Track News as Analysts Boost Targets

Disc Medicine (IRON) Stock Soars on FDA Fast-Track News as Analysts Boost Targets

Disc Medicine shares jumped 25.5% to $93 on October 17, 2025, after the FDA granted a Commissioner’s National Priority Voucher for its lead drug, bitopertin. The company filed a New Drug Application for bitopertin in late September; with the voucher, an approval decision could come as soon as late December. Several analysts raised their price targets sharply following the FDA news.
17 October 2025
·

Stock Market Today

  • UiPath Launches Coding Agents Platform, Gains UAE Cybersecurity Certification Amid Falling Shares
    June 10, 2026, 8:49 AM EDT. UiPath (NYSE:PATH) has introduced "UiPath for Coding Agents," enhancing automation deployment with better orchestration and governance. Additionally, it secured a key cybersecurity certification in the UAE, enabling the Automation Cloud's use by Tier 1 enterprises and government bodies. Despite these advances, PATH's stock trades near $10.75, down 32.3% year-to-date and 84.6% over five years. The developments boost UiPath's product capabilities and customer trust, critical for growth in software automation. Investors should watch for adoption rates of the new platform and potential UAE contracts that could impact future revenue. Currently, the stock trades 19% below analyst targets and is deemed undervalued by Simply Wall St, although momentum remains slightly negative.

Latest articles

Nuvalent Trades Close to $124 After GSK’s $10.6 Billion Offer

Nuvalent Trades Close to $124 After GSK’s $10.6 Billion Offer

10 June 2026
Nuvalent soared 39.28% to $123.25 after GSK agreed to buy the company for $124 per share in cash, leaving a narrow 0.6% spread as investors shift focus to the $10.6 billion merger’s tender-offer timing, antitrust review, and FDA decision dates for two lung-cancer drugs in September and November 2026.
IREN Stock Pauses as Nvidia Rally Cools Before Holiday

IREN Shares Fall Again; Microsoft AI Cloud Agreement Still in Focus

10 June 2026
IREN plunged 8.73% to $54.02 Tuesday and slid another 3.72% premarket as investors weighed Wall Street’s bullish calls on its AI cloud buildout against a tech and crypto selloff; the stock’s fate now hinges on IREN’s ability to deliver Microsoft- and Nvidia-linked AI infrastructure on schedule, with the Microsoft contract at risk if timelines slip.
Go toTop